Tivozanib: Phase II started

Aveo and Astellas began the double-blind, crossover, international Phase II TAURUS trial to compare 1.5 mg oral tivozanib daily for 3 consecutive weeks of a 4-week cycle for 12 weeks vs. 50 mg oral Sutent daily for 4 consecutive weeks of a 6-week cycle for 12 weeks in about 160 patients with metastatic RCC who have received no prior systemic therapy. ...